A small non-randomized retrospective study of a drug called pazopanib has shown that it increases children’s survival without ...

Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...

Survival rates from small trial suggest that adding pazopanib to standard treatment for Ewing sarcoma in children may extend lives without adding severe toxicity.

Campo Verde will be without head coach Ryan Freeman for the third straight week as he takes time to be with his daughter, who ...

Michael Perez has been running with a football for as long as he can remember. However, he received a medical diagnosis that ...

Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free ...

THURSDAY, Oct. 23, 2025 (HealthDay News) — Kids with a rare bone cancer might live longer if prescribed a drug that blocks ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

The human body is an amazing thing. It heals itself, fights off sickness, and somehow manages to store a lifetime’s worth of memories. Honestly, its capabilities seem endless. But let’s be real, it’s ...

Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...